Aptamarker prediction of brain amyloid-B status in cognitively normal individuals at risk for Alzheimer’s disease Abstract: The traditional approach to biomarker discovery for any pathology has been through hypothesis-based research one candidate at a time. The objective of this study was to develop an agnostic approach for the simultaneous screening of plasma for consistent molecular differences between a group of individuals exhibiting a pathology and a group of healthy individuals. To achieve this, we focused on developing a predictive tool based on plasma for the amount of brain amyloid-β deposition as observed in PET scans. The accumulation of brain amyloid-β […]

NeoNeuro, an aptamer company based in Paris, announced today that it has received an investment of up to $363,000 from the Alzheimer’s Drug Discovery Foundation’s (ADDF) Diagnostics Accelerator, an initiative that aims to fast-track the development of novel biomarkers for the early detection of Alzheimer’s disease and related dementias. This investment supports the project entitled “Extension study to determine brain Aβ status in blood with Aptamarkers.” This award enables NeoNeuro to further explore their discovery of the use of Aptamarkers for brain amyloid status to an analysis of 500 individuals from a mixture of cohorts including the  Australian Imaging, Biomarker […]

Link to article: Blood based diagnostics of Alzheimer”s disease

We will be attending the 14th. International Conference on Alzheimer’s and Parkinson’s Disease (AD/PD) March 26- 31, Lisbon, Portugal Poster: Combined Use of Aptamer Libraries and Known Biomarkers forPrediction of A-ß Brain Lesion Accumulation from Blood Plasma

We will be attending the 11th Clinical Trials on Alzheimer’s Disease (CTAD) October 24th. to October 27 th., 2018 Barcelona Spain         Poster: Novel use of aptamer libraries for prediction of amyloid-ß PET status from blood serum

NeoNeuro will be attending AAIC in Chicago, July 22-26, 2018.

http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0190212  

NeoNeuro SAS has entered into a collaboration under the leadership of Professor Harald Hampel to work with the INSIGHT cohort for the application of the Aptamarker platform to pre-AD samples. The INSIGHT cohort is an innovative study of Alzheimer’s disease, and one of the first in the world to monitor healthy subjects at-risk. NeoNeuro are using this cohort to extend their validation of the Aptamarker platform for Alzheimer’s disease to the diagnosis of amyloid status in healthy elderly subjects. INSIGHT is made possible through an innovative new scheme in medical research, a multi-partner foundation that focuses the Investissements d’Avenir (Investment […]

NeoNeuro will be attending BIO-Europe 2017. Dr. Penner will be available for meetings through the conference partnering portal

NeoNeuro is pleased to announce that they have contracted BlueDil as a supporting partner in their quest to raise seed financing.  BlueDil co-founders ,Dominique Corneillo and Sylvain Forget, bring a combined 60 years of experience in the pharmaceutical industry involving all aspects of the health science ecosystem. NeoNeuro has developed a novel platform (Aptamarkers) for the stratification of patients of Alzheimer’s disease based on blood samples. The Aptamarker platform is based on next generation sequence analysis of selected aptamer libraries applied to individual blood samples. Financing is being sought on an equity investment level as well as strategic partnerships with […]